Preparation and Immune Protective Efficacy Evaluation of PCV2d Cap-COS Bioconjugate Candidate Vaccine

PCV2d Cap-COS生物偶联候选疫苗的制备及免疫保护效力评价

阅读:1

Abstract

Porcine circovirus type 2 (PCV2) is one of the major pathogens currently threatening the global swine industry. The capsid protein (Cap) of PCV2 is a key antigen for developing subunit vaccines. In this study, we established a bioconjugation strategy using chitosan oligosaccharide (COS) to construct a covalently linked PCV2d Cap-COS complex via thiol-maleimide click chemistry. Immunization and challenge experiments in mice demonstrated that when formulated with JLC-3 adjuvant, the PCV2d Cap-COS complex induced stronger and more durable specific immune responses, significantly improved the average daily weight gain postchallenge, and effectively alleviated histopathological damage in the lungs and kidneys. These findings indicate that the PCV2d Cap-COS complex enhances both antigen structure and immunogenicity, offering a novel strategy and experimental evidence for developing high-efficacy PCV2d subunit vaccines.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。